Abrocitinib is an oral, small molecule, Janus kinase (JAK) 1 inhibitor mukugadzirwa kwekurapa kwevakuru nevechiri kuyaruka vane pakati kusvika kune yakaoma atopic dermatitis.

Abrocitinib iri kuferefetwa mukuedzwa kwekiriniki NCT03796676 (JAK1 Inhibitor Ine Medicated Topical Therapy in Adolescents With Atopic Dermatitis).

Abrocitinib parizvino iri kugadzirwa nePfizer yekurapa atopic dermatitis (eczema).Iyo yekuongorora yemuromo kamwe-zuva nezuva Janus kinase 1 (JAK1) inhibitor.

Atopic dermatitis (AD) chirwere cheganda chakaoma, chisingaperi, chinoratidzwa nepruritic, kukwenya kwakanyanya, uye eczematous maronda anobata chikamu che25% chevana uye 2% kusvika 3% yevakuru pasi rose.Abrocitinib is selective inhibitor yeJanus kinase-1 (JAK1) enzyme inhibiting the inflammatory process.Naizvozvo, isu takavavarira kuongorora kushanda uye kuchengetedzwa kweabrocitinib yepakati-kusvika-yakanyanya AD.

Abrocitinib in dose 100 mg kana 200 mg mushonga unoshanda, unobvumirwa zvakanaka, uye unovimbisa mukurapa varwere vane pakati-kusvika-yakanyanya atopic dermatitis.Zvisinei, kuongorora kwaifarira kushanda kweabrocitinib 200 mg pamusoro pe 100 mg, asi migumisiro yakadai sekusvotwa uye musoro zvinogona kuitika zvakanyanya ne 200 mg.